RESTORE SIGNED
NEURONAL SELF-RENEWAL BY ANTIGEN-SPECIFIC TOLERIZATION IN MULTIPLE SCLEROSIS REINSTALLING THE BALANCE BETWEEN INFLAMMATION AND REGENERATION
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0RESTORE project word cloud
Explore the words cloud of the RESTORE project. It provides you a very rough idea of what is the project "RESTORE" about.
Project "RESTORE" data sheet
The following table provides information about the project.
| Coordinator |
UNIVERSITEIT ANTWERPEN
Organization address contact info |
| Coordinator Country | Belgium [BE] |
| Project website | https://www.h2020restore.eu/ |
| Total cost | 5˙357˙032 € |
| EC max contribution | 5˙357˙032 € (100%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SC1-2017-Single-Stage-RTD |
| Funding Scheme | RIA |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-01-01 to 2022-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | UNIVERSITEIT ANTWERPEN | BE (ANTWERPEN) | coordinator | 911˙176.00 |
| 2 | INSTITUT CATALA DE LA SALUT | ES (BARCELONA) | participant | 1˙170˙212.00 |
| 3 | Stichting Sanquin Bloedvoorziening | NL (Amsterdam) | participant | 911˙250.00 |
| 4 | UNIVERSITAIR ZIEKENHUIS ANTWERPEN | BE (EDEGEM) | participant | 660˙056.00 |
| 5 | UNIVERSIDAD DE NAVARRA | ES (PAMPLONA) | participant | 625˙000.00 |
| 6 | ICOMETRIX NV | BE (LEUVEN) | participant | 530˙500.00 |
| 7 | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER | DE (MUENSTER) | participant | 363˙837.00 |
| 8 | STICHTING LYGATURE | NL (UTRECHT) | participant | 185˙000.00 |
Map
Project objective
Multiple sclerosis (MS) is an inflammatory neurodegenerative disease of the central nervous system for which no cure is currently available. It is the leading cause of non-traumatic disabling neurological disease in young adults with more than 500,000 people affected in Europe. As chronic inflammatory processes drive the neurodegeneration, we hypothesize that improved clinical outcome can be achieved by restoring the balance between inflammation and the remaining capacity of neuronal self-renewal. In this context, cell therapy that specifically targets the damaging immune reactions that cause MS, thereby reducing the autoreactive, inflammatory assaults in MS without affecting protective immunity against pathogens and cancer, can be a promising approach to allow for more repair. Recently, we set-up a collaborative network of European centers working in cell therapy (COST Action BM1305). From this, a multidisciplinary team from four different EU countries (B, ES, NL and GER) with two additional partners now aims to safely reach the next level of testing and joins efforts to bring antigen-specific cell therapy for MS to the clinic. Our objectives are to evaluate safety, clinical practicality and demonstrate first proof-of-principle of therapeutic efficacy of antigen-specific tolerance-inducing dendritic cells (tolDC) in MS patients in two single-center clinical trials. All regulatory approvals are already in place. Coordinated patient monitoring and centralized MRI monitoring, including radiological correlates of neurodegeneration, and immunomonitoring will enable us to directly compare results between trials and enable consented biobanking, data safeguarding and accessibility to support future efforts in the field of MS therapy. ReSToRe focuses on the advancement of an innovative cell therapy approach with the potential to improve the lives of patients suffering from MS, a currently untreatable disease. This would represent a breakthrough for healthcare in MS.
Deliverables
| Certificates of clinical training | Documents, reports | 2019-08-30 14:59:36 |
Take a look to the deliverables list in detail: detailed list of RESTORE deliverables.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2019 |
Willekens B, Presas-RodrÃguez, Mansilla M, Derdelinckx J, Lee W-P, Nijs G, De Laere M, Wens I, Cras P, Parizel PM, Van Hecke W, Ribbens A, Billiet T, Adams G, Couttenye M, Navarro-Barriuso J, Teniente-Serra A, Quirant-Sánchez B, López-DÃaz de Cerio A, Inogés S, Prósper F, Kip A, Verheij H, Gross CC, Wiendl H, van Ham SM, ten Brinke A, Barriocanal AM, Massuet-Vilamajó A, Hens N, Berneman Z, Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonized study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration published pages: , ISSN: 2044-6055, DOI: |
BMJ Open accepted for publication 23/7/2 | 2019-09-05 |
| 2018 |
Barbara Willekens, Nathalie Cools Beyond the Magic Bullet: Current Progress of Therapeutic Vaccination in Multiple Sclerosis published pages: 401-410, ISSN: 1172-7047, DOI: 10.1007/s40263-018-0518-4 |
CNS Drugs 32/5 | 2019-09-05 |
| 2019 |
Anja ten Brinke, Marc Martinez-Llordella, Nathalie Cools, Catharien M. U. Hilkens, S. Marieke van Ham, Birgit Sawitzki, Edward K. Geissler, Giovanna Lombardi, Piotr Trzonkowski, Eva Martinez-Caceres Ways Forward for Tolerance-Inducing Cellular Therapies- an AFACTT Perspective published pages: , ISSN: 1664-3224, DOI: 10.3389/FIMMU.2019.00181 |
Frontiers in Immunology 10 | 2019-09-05 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESTORE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RESTORE" are provided by the European Opendata Portal: CORDIS opendata.